Hims & Hers: Ride the Relief, Not the Euphoria

Hook & thesis

Hims & Hers (HIMS) erupted higher on 03/09/2026 after the company announced a deal with Novo Nordisk that resolves a major patent dispute and permits HIMS to sell Wegovy pills and Ozempic injections on its telehealth platform. The headline removes a severe legal overhang that had driven the stock into deeply oversold territory and forced sharp de-rating. That doesn’t mean the name is back to being a stable long-term buy today, but it does open a clear tactical opportunity: initiate a controlled long for the mid term while protecting capital with a concrete stop.

My trade: buy at $22.30, stop at $16.50$34.00 — mid-term (45 trading days) horizon. Why this setup? The company’s market cap of roughly $5.05 billion and forward multiples (P/E ~ 30.7, EV/Sales ~ 1.85) imply the market is willing to pay for a re-accelerating top line and distribution optionality. The Novo Nordisk deal and international acquisition of Eucalyptus give visible growth levers; the trade attempts to capture the near-term normalization while limiting downside from renewed GLP-1 volatility or execution slips.

What Hims & Hers does and why the market should care

Hims & Hers operates a direct-to-consumer telehealth and e-commerce platform connecting patients with clinicians for conditions like mental health, sexual health, dermatology and primary care. The platform’s economics improve as higher-margin chronic therapies - most notably GLP-1 weight-loss drugs - scale through its telemedicine distribution. That addressable market and the stickiness of recurring consumer subscriptions are why investors paid up before the legal scare.

Facts and figures that matter

Context from recent events

Two corporate developments changed the thesis in early March. First, management and Novo Nordisk resolved litigation and agreed to a commercial arrangement to distribute weight-loss medications on the HIMS platform. Second, HIMS is pursuing international expansion via its acquisition of Eucalyptus for up to $1.15 billion, a deal expected to close mid-2026. Those two items reduce headline risk and add growth optionality beyond the U.S. market.

Why that matters quantitatively

The company has signaled ambition toward roughly $2.8 billion of revenue in 2026. If HIMS can restore at least a portion of GLP-1 sales while growing its non-GLP-1 verticals (telehealth subscriptions, hair, sexual health), the current valuation - market cap of ~$5.05B and an EV of ~$4.33B - starts to look less stretched. Free cash flow is positive (~$57M) and the company appears capable of incremental margin expansion as higher-margin Rx sales scale and Eucalyptus contributes internationally.

Technicals & market structure

The move on 03/09/2026 ripped volume to ~174.5M shares traded intraday versus a 30-day average of ~37M, indicating squeeze-like activity and short-covering. Short interest has been elevated; the 02/13 settlement showed ~81M shares short with days-to-cover ~1.72, which can amplify rallies but also creates volatility. Momentum indicators are not uniformly overbought - RSI sits near 59 and the MACD shows nascent bullish momentum - implying there’s room for a measured continuation but also room for pullbacks back toward the 20- and 50-day averages.

Valuation framing

At roughly 30.7x P/E (snapshot) and EV/Sales ~1.85x, HIMS trades like a growth company with operational leverage but not like a pure momentum name pricing in rapid expansion. Historically, the stock hit $70 in mid-2025 when GLP-1 dynamics were at peak scarcity; the post-settlement price is materially lower, but still above the depressed lows of late February when legal uncertainty peaked. The math here is binary - if HIMS re-captures GLP-1 distribution at a meaningful scale and integrates Eucalyptus successfully, the present multiples compress into growth; if GLP-1 pricing collapses or regulatory headwinds re-emerge, multiples can rerate lower quickly.

Catalysts (timed)

• 03/09/2026 - Novo Nordisk deal roll-out and early dispensing metrics - initial sales data could sustain the rally or expose adoption friction.
• Mid-2026 - Eucalyptus acquisition close and early international performance indicators - any sign of revenue acceleration from UK/AU/DE will matter.
• Upcoming quarterly report - guidance for Q1/2026 and cadence commentary will be a decisive read on GLP-1 durability.
• Short-interest dynamics - a lower days-to-cover after heavy buying would reduce squeeze risk but also cap further quick gains.

Trade plan (actionable)

Entry: $22.30 - enter on a disciplined fill at or near the current level to capture post-deal normalization rather than chasing a higher late-day close.
Stop: $16.50 - a hard stop below the immediate support band but comfortably above the 52-week low ($13.74) to limit downside if GLP-1 headwinds or execution issues reappear.
Target: $34.00 - reflects ~52% upside from entry and prices in renewed growth and margin leverage while remaining below the prior all-time peak.
Horizon: mid term (45 trading days). Expect the trade to play out over multiple catalyst events: initial Novo Nordisk roll-out metrics and the next quarterly update. Close or trim the position earlier if the deal fails to generate measurable dispensing or guidance is trimmed.

Risk level: high. This is a tactical trade sized for investors who can tolerate material intraday swings.

Risks & counterarguments

• GLP-1 commercialization risk: The Novo Nordisk agreement removes the legal cloud, but pricing pressure and competition in GLP-1s can quickly compress revenue and margins. If competitors cut price aggressively, unit economics could deteriorate.
• Execution and integration risk: The $1.15B Eucalyptus purchase expands international exposure but creates integration complexity. Delays or cost overruns would be a material negative.
• Macroeconomic/market risk: Broader market dislocations - for example, the oil-driven market selloff on 03/09/2026 - can wipe out rally-driven gains even when company fundamentals are steady.
• High short interest and volatility: Elevated short positioning can both fuel rallies and exacerbate falls; intraday moves may be amplified and unpredictable.
• Balance sheet leverage: Debt/equity is notable (roughly 1.8x), which increases refinancing and interest-rate sensitivity if growth stalls.

Counterargument

One could argue this is a classic squeeze/recovery rally without sustainable revenue backing — guidance misses and continuing GLP-1 demand normalization could cause the upside to evaporate quickly. That is plausible: management already flagged softer-than-expected near-term guidance in recent commentary, and if early Novo Nordisk dispensing metrics disappoint, the market may test the recent lows again. That’s why a hard stop and a specific target are critical; the trade is not a blanket endorsement of buy-and-hold.

Conclusion - stance and what would change my mind

Stance: Tactical long - Not selling yet. The Novo Nordisk resolution materially reduces headline legal risk and creates a path for revenue restoration. Paired with international expansion via Eucalyptus, the company has a credible roadmap to regain momentum. However, execution and GLP-1 market dynamics remain key. Enter at $22.30, protect at $16.50, and take profits at $34.00 within a mid-term window (45 trading days).

What would change my mind: If early Novo Nordisk roll-out metrics show low conversion or if guidance is cut again on the next quarterly report, I would flip to neutral/short and tighten stops immediately. Conversely, if HIMS posts clear sequential revenue acceleration, healthy gross margins on GLP-1 sales, and early positive international traction, I would remove the stop and re-rate the position to a longer-term growth holding.

Key takeaways

• Material legal overhang removed on 03/09/2026 - that was the proximate cause of the recent crash.
• Valuation (P/E ~30.7x, EV/Sales ~1.85x) prices growth but still leaves room for upside if GLP-1 sales recover and international expansion contributes.
• Trade is tactical and high-risk: enter at $22.30, stop at $16.50, and target $34.00 on a mid-term (45 trading days) horizon.
• Watch early Novo Nordisk dispensing data, Q1 guidance, and Eucalyptus integration as the primary catalysts.